Company profile: IntegraGen
1.1 - Company Overview
Company description
- Provider of molecular marker development for central nervous system and metabolic diseases, and sequencing/bioinformatics services: exome, custom gene panel, and whole genome sequencing; cancer and genetic disease pipelines; proprietary software for variant selection and clinical-grade results; MERCURY oncology reporting tool; and OncoXPLORE cancer gene panel for biomarker validation and tumor characterization.
Products and services
- Bioinformatics and Data Analysis: Delivers clinical-grade pipelines for cancer and genetic disease analysis, with proprietary variant-selection software access and comprehensive processing producing clinical grade sequencing results
- MERCURY: Constructs an online oncology platform converting raw sequencing data into research-use molecular reports, customizable for various gene panels
- Whole Genome Sequencing: Produces species-agnostic genomic datasets for any species using a range of library preparation methods and integrated bioinformatics analysis pipelines to comprehensively profile entire genomes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to IntegraGen
Fluxion Biosciences
HQ: United States
Website
- Description: Provider of cellular analysis tools and drug discovery applications, built on a proprietary microfluidic platform enabling precise cellular manipulation, low-volume compound addition, environmental control, and software-based data acquisition. Offerings include BioFlux Systems, IonFlux Mercury Systems, CellRaft AIR System, CERO 3D Incubator & Bioreactor, CASY Cell Counter & Analyzer, and TIGR Tissue Grinder and Dissociator.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fluxion Biosciences company profile →
AltheaDx
HQ: United States
Website
- Description: Provider of molecular diagnostics and PCR-based services, including molecular biomarker discovery, assay development and validation, prospective/retrospective clinical trial testing, and gene expression and genotyping analysis for pre-clinical and clinical applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AltheaDx company profile →
Applied Microarrays
HQ: United States
Website
- Description: Provider of design, optimization and manufacturing services for DNA and protein biosensors and other microarrays on glass, plastic and semiconductors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Applied Microarrays company profile →
DermTech
HQ: United States
Website
- Description: Provider of non-invasive qPCR assays for skin samples collected via adhesive tape biopsy, analyzing multiple gene targets' RNA expression. Offerings include the DermTech Melanoma Test, a genomic test using adhesive tape-collected skin cells to detect markers associated with melanoma with a 99% negative predictive value, anticipated to be provided through a CLIA-certified laboratory in San Diego.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DermTech company profile →
ProQR
HQ: The Netherlands
Website
- Description: Provider of RNA therapeutics and editing platforms for severe genetic rare diseases. Develops Axiomer RNA base-editing technology and Trident pseudouridylation platform, with programs AX-0810 for cholestatic diseases and AX-1412 for cardiovascular diseases, and product candidates QR-010, QR-110, and QR-313 for cystic fibrosis, Leber's congenital amaurosis type 10, and dyastrophic epidermolysis bullosa; partners with Eli Lilly.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProQR company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for IntegraGen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to IntegraGen
2.2 - Growth funds investing in similar companies to IntegraGen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for IntegraGen
4.2 - Public trading comparable groups for IntegraGen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →